KRAS and urinary bladder carcinoma: Previously, we had reported the anti-tumor effect of miR-143 within an immunodeficient xenograft mouse model by targeting KRAS and its effector molecules in bladder cancer cells [36], bladder cancer cells [12], and colon cancer cells [11].